Apellis (APLS) director Mikael Dolsten submits initial Form 3 insider filing

Rhea-AI Filing Summary

Apellis Pharmaceuticals, Inc. director Mikael Dolsten filed an initial statement of beneficial ownership on Form 3. This filing establishes him as an insider for reporting purposes, but it does not list any specific stock transactions or changes in his holdings.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Dolsten Mikael

(Last) (First) (Middle)

C/O APELLIS PHARMACEUTICALS, INC.

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/02/2026

3. Issuer Name and Ticker or Trading Symbol
Apellis Pharmaceuticals, Inc. [ APLS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ David Watson, attorney-in-fact for Mikael Dolsten	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Apellis (APLS) Form 3 filing for Mikael Dolsten show?

The Form 3 filing shows that Mikael Dolsten is a director of Apellis Pharmaceuticals, Inc. It serves as his initial insider ownership statement and does not report any stock purchases or sales.

Did Mikael Dolsten buy or sell Apellis (APLS) shares in this Form 3?

No stock purchases or sales are reported in this Form 3 for Mikael Dolsten. The filing only identifies him as a director and establishes his status as an insider for future reporting.

Why is Apellis (APLS) director Mikael Dolsten filing a Form 3?

Mikael Dolsten is filing Form 3 because he is a director of Apellis Pharmaceuticals, Inc. Form 3 is required when someone becomes an insider and begins being subject to ongoing ownership reporting rules.

Does the Apellis (APLS) Form 3 include any transaction details?

The Form 3 for Apellis director Mikael Dolsten does not include any transaction details. It lists no stock buys, sells, acquisitions, or dispositions and functions solely as an initial ownership statement.

What insider role is disclosed for Mikael Dolsten at Apellis (APLS)?

The filing discloses that Mikael Dolsten serves as a director of Apellis Pharmaceuticals, Inc. This role makes him an insider subject to Form 3, 4, and 5 reporting requirements going forward.